| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,145 |
2,094 |
$379K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,971 |
2,908 |
$275K |
| 99051 |
|
2,474 |
2,402 |
$60K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
690 |
684 |
$37K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
377 |
377 |
$29K |
| 87428 |
|
70 |
70 |
$6K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
120 |
115 |
$5K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
119 |
114 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
185 |
184 |
$2K |
| 98966 |
|
136 |
131 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
117 |
116 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
87 |
86 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
79 |
78 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
32 |
32 |
$784.82 |
| 81002 |
|
192 |
187 |
$644.76 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
13 |
13 |
$401.57 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
14 |
13 |
$337.82 |
| 87510 |
|
13 |
13 |
$309.14 |
| 87480 |
|
13 |
13 |
$309.14 |
| 87660 |
|
13 |
13 |
$285.36 |
| 99441 |
|
15 |
14 |
$243.90 |
| 81025 |
|
12 |
12 |
$215.16 |
| 80053 |
Comprehensive metabolic panel |
12 |
12 |
$174.48 |
| 87081 |
|
12 |
12 |
$94.44 |